lymphocytic

MaxCyte and Medinet to Present at the 13th Annual Meeting of the International Society for Cellular Therapy (ISCT) in Sydney, Australia

... Phase I/II clinical study fortreatment of chronic lymphocytic leukemia (CLL) and a Phase IIastudy using engineered stem cells for the treatment of primaryPulmonary Arterial Hypertension (PAH). In addition there areadvanced preclinical programs in oncology and regenerativemedicine. More than 16 commercial and ac...

Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association

...atients with B-cell malignancies, includingchronic lymphocytic leukemia, mantle cell lymphoma and multiplemyeloma. Sunesis plans to present preliminary data from thisongoing Phase 1 trial by year's end. Data on SNS-595 and SNS-032 were presented at the 12th Congressof European Hematology, organized by The Europ...

Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection

...in therecent Phase 3 trial of Genasense in chronic lymphocytic leukemia(CLL). A second phase of the program is testing escalating doses ofGenasense administered as a 2-hour IV infusion. Single 150 mgdoses, as well as repeated 150 mg doses administered daily for 5consecutive days, have been well-tolerated. To ...

Santaris Pharma Presents Positive Clinical Data on SPC2996 in Chronic Lymphocytic Leukaemia

...OR EDITORS Chronic Lymphocytic Leukaemia Chronic lymphocytic leukaemia (CLL) is the most common form ofleukaemi... and this isparticularly the case in human chronic lymphocytic leukaemia andlymphoma where it acts to prolong the life of malignant white bloodcells. Drugs which l...

MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting

...activity observed in patientswith refractory acute lymphocytic leukemia (ALL). Gliadel(R) Wafer(polifeprosan 20 with carmustine implant) was the subject of twoposters with one detailing the impact of multimodal therapy thatincluded Gliadel implantation, followed by treatment with radiationand concurrent temozolo...

MGI Pharma, Inc. Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting

...activityobserved in patients with refractory acute lymphocytic leukemia(ALL). Gliadel Wafer (polifeprosan 20 with carmustine implant) wasthe subject of two posters with one detailing the impact ofmultimodal therapy that included Gliadel implantation, followed bytreatment with radiation and concurrent temozolomid...

Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas

... Stilgenbauer, S. & Flinn, I.W. (2004) Chronic lymphocytic leukemia. Hematology (American Society of H... A. (2005) Biology and treatment of chronic lymphocytic leukemia. Annals of Oncology, 16(Suppl. 2), ii113-123. (3) Kuriakose, P. (2005) Targeted t...

Innovive Pharmaceuticals to Present Interim Data from Phase I Study of INNO-406 at the American Society of Clinical Oncology Annual Meeting

... myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant of imatinib"Abstract Number: 7046Session: General Poster Session, Leukemia, Myelodysplasia and Transplantation, Poster Board #L2...

Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN

...ct is indicated forthe treatment of B-cell chronic lymphocytic leukemia (B-CLL) inpatients who have been treated with alkylating agents and who havefailed fludarabine therapy. Determination of the effectiveness ofCampath is based on overall response rates. Comparative, randomizedtrials demonstrating increased su...

Santaris Pharma presents positive preclinical data on SPC2996 at the American Association for Cancer Research

...to editors Chronic Lymphocytic Leukaemia Chronic lymphocytic leukaemia (CLL) is the most common form ofleukaemi... and this isparticularly the case in human chronic lymphocytic leukaemia andlymphoma where it acts to prolong the life of malignant white bloodcells. Drugs which l...

Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in Cancer Animal Models

... cancers, including non-Hodgkin'slymphoma, chronic lymphocytic leukemia and acute lymphocyticleukemia. Single dose treatments of a fully human anti-CD19antibody drug conjugate demonstrated in vivo anti-tumor efficacyleading to the regression of established subcutaneous tumors andsystemic tumors in leukemia xenog...

Sunesis Presents Data Supporting SNS-032's Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting

...al trialfor B-cell malignancies, including chronic lymphocytic leukemia,multiple myeloma and mantle cell lymphoma. Non-clinical studieswere conducted by Sunesis evaluating SNS-032's mechanism of actionand in vitro activity against human multiple myeloma cell lineRPMI-8226. Acting through inhibition of CDKs 2, 7,...

CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting

...gistically with Bortezomib in human chronic lymphocytic leukemia (CLL) cells in association with NF-.B inactivation," (Abstract #1835) during the conference's Targeted Agents and Other Novel Therapies poster session on Monday, April 16th in the Exhibit Hall, Poster Section 7 on Poster...

Data from Preclinical Studies of Gilead Nucleotide Compound GS 9219 to be Presented at AACR

...of patients withnon-Hodgkin's lymphoma and chronic lymphocytic leukemia later thisyear at cancer centers in the United States. About GS 9219 GS 9219 is a prodrug of the nucleotide analog PMEG(9-(2-phosphonylmethoxyethyl)guanine). It is selectively enrichedin lymphocytes, and therefore may have potential appl...